Roche FY Revenues: 58.3 billion CHF (-5%) FY Earnings 15.1 billion CHF (+7%) Pharmaceuticals sales were down 2% for the year. Newly launched medicines had continued sales growth (+32%), including Tecentriq, Hemlibra, Ocrevus, Perjeta and Kadcyla, offsetting the impact of competition from biosimilars for the established medicines Herceptin, Avastin and MabThera/Rituxan, with an estimated combined CHF 5.1 billion of sales decline in the U.S, Europe and Japan. The COVID-19 pandemic had an overal...